Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights

NEXT STORY
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
PREV STORY
CorMedix Inc. Announces a Change to its Senior Leadership
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oxford Immunotec Ranked Among Deloitte’s 2016 Technology Fast 500™

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec ...

author_avatar
NASDAQ Market News

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer

Basel, 17 January 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...

author_avatar
NASDAQ Market News

Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

author_avatar
NASDAQ Market News